A股申购 | 生物医药企业必贝特(688759.SH)开启申购 5个产品处于I期临床试验阶段

Core Viewpoint - The company Bibeite (688759.SH) has initiated its subscription with an issue price of 17.78 yuan per share, focusing on innovative drug development for major diseases such as cancer and autoimmune disorders [1]. Company Overview - Bibeite is a biopharmaceutical company that emphasizes clinical value and is dedicated to the independent research and development of innovative drugs [1]. - The company has one approved breakthrough therapy drug, BEBT-908, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and several other products in various stages of clinical trials [1][2]. Product Pipeline - BEBT-908 is the first-in-class small molecule dual-target inhibitor designed for HDAC/PI3Kα, approved for multiple hematologic malignancies and solid tumors [1]. - Other products include: - BEBT-209, currently in Phase III clinical trials [1]. - BEBT-109, which has been approved to start Phase III clinical trials [1]. - Five additional products are in Phase I clinical trials, and several more are in preclinical research [1][3]. Financial Performance - The company reported net losses of approximately 188 million yuan in 2022, 173 million yuan in 2023, and an expected loss of 55.998 million yuan in 2024 [4]. - Bibeite has not yet achieved profitability and anticipates significant ongoing research and development expenditures, which will likely prevent any profit distribution or cash dividends in the short term [4]. Financial Metrics - Total assets as of December 31, 2024, are projected to be 332.4771 million yuan, down from 441.8725 million yuan in 2023 and 587.2168 million yuan in 2022 [4]. - The company's equity attributable to shareholders is expected to be 290.2201 million yuan in 2024, compared to 318.1196 million yuan in 2023 and 468.3349 million yuan in 2022 [4]. - The debt-to-asset ratio for the parent company is projected to be 12.38% in 2024, a decrease from 27.77% in 2023 and 20.23% in 2022 [4].